



Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry

Journal home page: www.ajpamc.com



BIOCHEMICAL AND HEMATOLOGICAL EVALUATIONS IN SUDANESE WOMEN WITH PREECLAMPSIA

Eltayeb Tayrab ^{*1,2} and Sohinda Saladdin²

¹Department of Chemical Pathology, National Ribat University, Faculty of Medical Laboratory Sciences, Khartoum, Sudan.

²Department of Medical Laboratories Science, College of Applied Medical Sciences, University of Bisha, Kingdom of Saudi Arabia.

ABSTRACT

Objectives of the study: The aim of this study was to evaluate the biochemical and hematological changes which occur in the serum of pregnant women with pre-eclampsia. **Materials and methods:** The study included 120 pregnant women with pre-eclampsia, beside 75 normotensive women at third trimester of pregnancy, served as control group. Serum uric acid, creatinine, urea, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) were measured using automated chemical analyzer. Serum sodium and potassium were measured using ion selective electrode. Complete blood count (CBC) was done using full automated hematology analyzer. Data were analyzed using IBM SPSS Statistics version 20. **Results:** The study revealed that the mean age of the women with pre-eclampsia was (28.11±6.45years), versus (29.18±6.35 years). The diastolic blood pressure was (152.29±17.67mmHg) versus (106.48±11.54mmHg) with P.value (0.000). The systolic blood was (122.80±5.57mmHg) versus (78.94±3.25mmHg) with P.value (0.000). Serum creatinine was (0.68±0.36mg/dl) versus (0.43±0.25mg/dl) with P.value (0.000). Uric acid was (6.96±2.07 mg/dl) versus (4.98±1.42mg/dl) with P value (0.000). The mean ALP was (130.70±46.12U/L) versus (83.85±17.67U/L) with P. value (0.000). The AST was (63.88±112.23 U/L) versus (29.60±12.07 U/L) with P.value (0.01). The ALT was (32.10±49.91 U/L) versus (18.18±8.55 U/L) with P.value (0.003). The mean of white blood cells (WBCs) was (9.44±4.18x10⁹/l) versus (8.22±2.77x10⁹/l) with P.value (0.015). The mean of platelets (PLTs) was (211.19±93.06x10⁹/l) versus (245.36±65.97x10⁹/l) with P.value (0.003). **Conclusion:** In Sudanese women with preclampsia; serum creatinine, uric acid, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and white blood cell count significantly increase, while platelets count significantly decrease.

KEY WORDS

Preeclampsia, Biochemical, Hematological evaluation, Sudan.

Author of correspondence:

Eltayeb Tayrab,
College of Applied Medical Sciences,
University of Bisha, Kingdom of Saudi Arabia.

Email: eltayebtayrab@gmail.com

INTRODUCTION

Pre-eclampsia (PE) is a multisystem disease unique to human pregnancy characterized by hypertension after 20 weeks of gestation¹, including proteinuria and edema^{2,3}. Precise etiology and definition of (PE) has changed several times^{4,5}. Pre-eclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide^{6,7}. Its incidence is 2-10% worldwide depending on the population studied⁴. In

developing countries it rank second only to anaemia, with approximately 7-10% of all pregnancies being complicated⁶. The incidence of (PE) reached 16% in some countries like Bangladesh⁸. Ideally; the diagnosis of (PE) should involve the use of biomarkers that reflect the underlying pathophysiology of the disease process⁵. Preeclampsia is characterized by elevated liver enzymes and low platelets^{9,1}. Serum creatinine level decreases during normal pregnancy mainly because of the combination of blood volume expansion; hyper filtration and oncotic pressure decrease¹⁰; but in (PE) serum creatinine levels varies widely from mild increase to dialysis requirement¹⁰.

Serum uric acid concentrations fall in early pregnancy due to an elevation in renal clearance secondary to increased glomerular filtration rate¹¹. Later in pregnancy the serum uric acid levels increase, possibly due to raised fetal production and a decline in uric acid clearance until the end of pregnancy¹². In (PE); hypoxia and ischemia of the placenta induce the expression of xanthine oxidase and therefore, increase the production of uric acid¹¹. When serum uric acid increased, birth weight significantly decreased¹³. Xanthine oxidoreductase is the enzyme that catalyzes the chemical reactions of purine catabolism to xanthine and then xanthine to uric acid, this enzyme is found mainly in the liver¹⁴. All markers of liver function are generally reduced or low during pregnancy due to the expansion of extracellular fluid. Hence; serum albumin, (AST), ALT) and total bilirubin are low compared with the non-pregnant state^{15,16}. In (PE) hyper vascularization and vasoconstriction of liver leads to liver cell injury and alteration of cell membrane permeability and damage to the cells which allows intracellular enzyme to leak into the blood ,leads to elevated liver enzymes¹⁷. The only exception is (ALP) which is elevated due to ALP of placental origin¹⁶. In the liver function the most sensitive change seen in (AST), but there is also a rise in (ALT)¹⁸. Almost all of patients with (PE) and abnormally elevated liver function tests had hyperuricaemia. Thus there seems to be a strong association between liver dysfunction and

hyperuricaemia in (PE)¹⁵. A rise in liver enzyme levels is always significant and needs to be followed carefully, severe liver impairment can be associated with liver swelling, which causes the epigastric pain and can lead to liver rupture¹⁸.

In (PE) hematological profile shows no significant change in haematocrit, but platelet count is significantly lower and neutrophil count is significantly higher¹⁹. When the platelet count is less than 50,000 per mm³ (50×10^9 per L) active bleeding may occur³.

Early screening for (PE) may allow vigilant antenatal surveillance and appropriate timing of fetal delivery in order to avoid serious sequelae⁶.

MATERIALS AND METHODS

This case control study was done during the period from September 2013 to July 2015; in Maternity Hospital and Ribat University Hospital in Khartoum- Sudan. Random blood samples were collected from 120 pregnant women with pre-eclampsia, and from 75 normotensive women at third trimester of pregnancy served as control group. Ten ml of blood were drawn from each subject by disposable plastic syringes then divided into 5ml in a plain container without anticoagulant; and another 5ml in EDTA tube for complete blood count (CBC) using full automated hematology analyzer (Sysmex). Serum preparation was done by the centrifugation at 3000 rpm for 10 minutes, and then stored at -20°C till the time of analysis. The serum sample was used for the measurement of urea, creatinine, uric acid, total protein, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP); using automated chemical analyzer (Mindary BS -210), while serum sodium and potassium were measured using (iron selective electron). Data were analyzed using IBM SPSS Statistics version 20. The mean and standard deviation was obtained, t test was used for the comparison studies, P value < 0.05 was considered significant. The ethical approval was obtained from Federal Ministry of Health and from National Ribat

University ethical committee. Informed and verbal consent was taken from individuals under study.

RESULTS

This study revealed that the mean age of the women with pre-eclampsia was (28.11 ±6.45years), while in the women with normal pregnancy was (29.18±6.35 years). The mean weight in the preeclamptic women was (79.34±8.97Kg), while in the control group was (77.42±5.81Kg). The mean of diastolic blood pressure in the preeclamptic women was (152.29±17.67 mmHg); while in the control group was (122.80±5.57 mmHg); with P.value (0.000). The mean of systolic blood pressure in the preeclamptic women was (106.48±11.54 mmHg); while in the control group was (78.94±3.25 mmHg); with P.value (0.000). The mean of urea in the women with pre-eclampsia was (26.26±13.84 mg/dl) versus (24.0400±9.76 mg/dl) in the women with normal pregnancy with no significant difference. Serum creatinine in the women with pre-eclampsia was (0.68±0.36mg/dl) versus (0.43±0.25mg/dl) in the women with normal pregnancy with P.value (0.000). The mean of sodium in the women with pre-eclampsia was (135.87±6.19908m.mol/l) versus (136.42±5.55 mmol/l) in the control group with no significant difference. The mean of potassium in the women with pre-eclampsia was (3.93±0.75 mmol/l) versus (4.20±0.88 mmol/l) in the control group with no significant difference. The mean serum uric acid in the women with pre-eclampsia was (6.96±2.07 mg/dl) versus (4.98±1.42mg/dl) in the women with normal pregnancy; with P.value (0.000). The mean of total protein in the women with pre-eclampsia was (6.14±0.78g/dl) versus (6.78±0.59g/dl) in the women with normal pregnancy with no significant difference. The mean of albumin in the women with pre-eclampsia was (2.82±0.62g/dl) versus (3.48±0.53g/dl) in the women with normal pregnancy with no significant difference. The mean of ALP in the women with pre-eclampsia was (130.70±46.12 U/L) versus (83.85±17.67U/L) in the women with normal pregnancy with P.value (0.000). The mean of AST in the women with pre-

eclampsia was (63.88±112.23 U/L) versus (29.60±12.07 U/L) in the women with normal pregnancy; with P.value (0.01). The mean of ALT in the women with pre-eclampsia was (32.10±49.91 U/L) versus (18.18±8.55 U/L) in the women with normal pregnancy; with P.value (0.003) (Table No.1). The mean of Hb in the women with pre-eclampsia was (11.35±1.61) versus (11.78±1.44) in the control group there was no significant change. The mean of PCV in the women with pre-eclampsia was (34.71±4.92) versus (35.36±4.84) in the women with normal pregnancy; there is no significant difference. The mean of MCV in the women with pre-eclampsia was (82.91±6.11) versus (83.99±4.16) in the women with normal pregnancy; there was no significant difference. The mean of MCH in the women with pre-eclampsia was (28.02±3.97) versus (28.55±2.44) in the women with normal pregnancy there was no significant difference. The mean of MCHC in the women with pre-eclampsia was (32.92±2.97) versus (32.89±1.99) in the women with normal pregnancy; there was no significant difference. The mean of RBC in the women with pre-eclampsia was (3.9442±0.77x10¹²/l) versus (4.00±0.71x10¹²/l) in the women with normal pregnancy; there was no significant difference. The mean of WBC in the women with pre-eclampsia was (9.44±4.18x10⁹/l) versus (8.22±2.77x10⁹/l) in the women with normal pregnancy; with P.value (0.015). The mean of PLTs in the women with pre-eclampsia was (211.19±93.06x10⁹/l) versus (245.36±65.97x10⁹/l) in the women with normal pregnancy; with P.value (0.003), (Table No.2).

DISCUSSION

Preeclampsia and its associated morbidity and mortality for both mother and fetus remain significant clinical problem; one of these complications is gestational hypertension, in the present study; both diastolic and systolic blood pressure significantly increase, which are in agreement with that reported by many authors like Akter *et al* (2014)¹³, Lowe *et al* (2014)²⁰, Redman *et al* (1976)²¹, Varma (1982)²² and Mustaphi *et al*

(1996)²³. During normal pregnancy blood pressure falls in first trimester and rises towards pre-conception by term as written by Lowe et al (2014)²⁰. Perinatal mortality rises with diastolic blood pressures above 90 mmHg as also reported by Lowe et al (2014)²⁰; the mean diastolic pressure in Sudanese women with preeclampsia is (152.29±17.67 mmHg). Women with pregnancy induced hypertension are at high risk of developing cardiovascular related diseases as found by Raijmakers et al (2003)²⁴. As uric acid is partly a surrogate marker of tissue involvement in preeclampsia as reported by James (2000)¹⁸. The data of the present work shows significantly increase in serum uric acid which is consistent with that reported by Akter et al; (2014)¹³, Lowe et al (2014)²⁰, Razia et al (2013)⁸, Rizwana et al (2015)²⁵, James (2000)¹⁸, Paneri et al (2011)²⁷. Rising level of serum urate is indication of preeclampsia progress and a good predictor for increased fetal risk as described by Redman et al (1976)²¹. On the other hand hyperuricaemia is quantitatively related to the outcome of the pregnancy for both the infant and the mother as written by Roger (2008)¹⁵.

The present study reveals significant increase in serum creatinine levels in the preeclamptic women; this finding is also reported by Paneri et al (2011)²⁶, Rizwana et al (2015)²⁵, Basima et al (2014)²⁷. In preeclampsia renal blood flow and glomerular filtration rate decrease; leading to endothelial

damage; hence appear elevated creatinine and decreased creatinine clearance; proteinuria, hyperuricaemia, oliguria; causing renal tubular necrosis and renal failure as mentioned by guidelines of RCOG (2010)²⁸.

In this study all liver enzymes (AST, ALT and ALP); significantly increase in the Sudanese women with preeclampsia, this finding are consistent with that found by (Paneri et al; 2011)²⁶, but Basima et al (2014)²⁷ found no significant difference in the level of ALP in the preeclamptic which is in disagreement with this study.

The elevation of liver enzymes especially AST and ALT was also reported by Remero et al (1988)²⁹ and Leela et al (2015)³⁰. This happen because in preeclampsia hyper vascularization and vasoconstriction of liver leads to liver cell injury and alteration of cell membrane permeability and damage to the cells which allows intracellular enzyme to leak in to the blood, leads to elevated liver enzymes as suggested by Madazila et al (1999)¹⁷.

The hematological profile shows that hematocrit, MCV, MCH, MCHC and RBC are not different between the preeclampsia group and their control, but platelet count is significantly lower and neutrophil count is significantly higher in the preeclamptic group; these finding also reported Anne et al (1996)¹⁹. Low platelets are also described by James (2000)¹⁸, Rizwana et al (2015)²⁵.

Table No.1: Biochemical parameters (urea, creatinine, sodium, potassium, uric acid, alkaline phosphatase (ALP), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in preeclampsic women (N =120) and their control (N=75)

S.No	Study groups (variable)	Mean	Std. Deviation	P value
1	Urea (mg/dl)	26.2667	13.84836	0.190
	Pre-eclampsic group	24.0400	9.76956	
2	Creatinine (mg/dl)	0.6842	0.36553	0.000
	Pre-eclampsic group	0.4387	0.25779	
3	Sodium (m.mol/l)	135.8750	6.19908	0.744
	Pre-eclampsic group	136.4286	5.55690	
4	Potassium (m.mol/l)	3.9393	0.75150	0.336
	Pre-eclampsic group	4.2000	0.88129	
5	Uric acid (mg/dl)	6.9650	2.07480	0.000
	Pre-eclampsic group	4.9893	1.42502	
6	T. protein (mg/dl)	6.142	0.7810	0.264
	Pre-eclampsic group	6.780	0.5991	
7	Albumin (g/dl)	2.828	0.6218	0.261
	Pre-eclampsic group	3.485	0.5373	
8	ALP (u/l)	130.7041	46.12225	0.000
	Pre-eclampsic group	83.8533	17.67017	
9	AST (u/l)	63.8833	112.23701	0.01
	Pre-eclampsic group	29.6000	12.07186	
10	ALT (u/l)	32.1083	49.91536	0.003
	Pre-eclampsic group	18.1867	8.55300	

Table No.2: Hematological parameters (Hb, PCV, MCV, MCH, MCHC, RBC, WBC and PLTs) in preeclampsic women (N =120) and their control (N=75)

S.No	Study groups	Mean	Std. Deviation	P value
1	Hb (g/dl)	11.3567	1.61691	0.059
	Pre-eclampsic group	11.7800	1.44886	
2	PCV (%)	34.7152	4.92316	0.376
	Pre-eclampsic group	35.3640	4.84156	
3	MCV (fI)	82.9108	6.11255	0.144
	Pre-eclampsic group	83.9920	4.16182	
4	MCH (pg)	28.0200	3.97660	0.248
	Pre-eclampsic group	28.5533	2.44851	
5	MCHC (g/dl)	32.9275	2.97420	0.924
	Pre-eclampsic group	32.8933	1.99671	
6	RBC (10 ¹² /l)	3.9442	0.77609	0.566
	Pre-eclampsic group	4.0067	0.71402	
7	WBC (10 ⁹ /l)	9.4467	4.18356	0.015
	Pre-eclampsic group	8.2280	2.77701	
8	PLTs (10 ⁹ /l)	211.1917	93.06475	0.003
	Pre-eclampsic group	245.3600	65.97105	

CONCLUSION

In Sudanese women with preeclampsia both systolic and diastolic blood pressures significantly increase; beside serum uric acid, creatinine, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and neutrophils also significantly increase, while platelets count significantly decrease. Early screening by using the simple biochemical and hematological profile seems to be useful to predict maternal complications in the management of women with preeclampsia.

ACKNOWLEDGEMENT

The authors are grateful to all the staff of the hospitals where the study was done, for providing facilities to perform this work.

CONFLICT OF INTEREST

We declare that we have no conflict of interest.

BIBLIOGRAPHY

1. Dennis A T. Management of pre-eclampsia: issues for anaesthetists, *Anaesthesia*, 67(9), 2012, 1009-1020.
2. Ana-maria V, Cristian A, Minodora O, Veronica V, Horia B, Radu V. The endothelial-platelet dysfunction in preeclampsia, *A Journal of Clinical Medicine*, 2(3), 2007, 214-221.
3. Lawrence Le, Patricia F. Hypertensive disorders of pregnancy, *American Family Physician*, 78(1), 2008, 94-100.
4. North R A, Taylor R S, Schellenberg J C. Evaluation of a definition of preeclampsia, *Br J Obstet Gynaecol*, 106(8), 1999, 767-773.
5. Ravi I T, Richard J J, Ananth K S. Hypertension during pregnancy, A disorder begging for pathophysiological support, <http://hyper.ahajournals.org/> by guest, 2015.
6. Patel T, Dudhat A. Relationship of serum uric acid level to maternal and perinatal outcome in patients with hypertensive disorders of pregnancy, *Gujarat Medical Journal (GMJ)*, 69(2), 2014, 45-47.
7. Al-Mulhim A A, Abu-Heija A, Al-Jamma F, El-Harith el-H A. Pre-eclampsia: maternal risk factors and perinatal outcome, *Fetal Diagn Ther*, 18(4), 2003, 275-80.
8. Razia S, Selina A, Nasima S, Fazlul Karim S M, Farhana A. Association of serum uric acid with preeclampsia: a case control study, *Delta Med Col J*, 1(2), 2013, 46-50.
9. Edward T C. Obstetrical anesthesia for patients with the syndrome of hemolysis, elevated liver enzymes and low platelets, *Canadian Journal of Anaesthesia*, 38(2), 1991, 227-233.
10. Fadi F, Caroline V, Veronique Fremeaux-Bacchi. Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy, *Clin J Am Soc Nephrol*, 7, 2012, 2100-2106.
11. El-Gharib M N, Mahfouz A E, Morad M A, Farahat M A. Prediction of gestational diabetes by measuring first trimester maternal serum uric acid concentration, *J Basic Clin Reprod Sci*, 2(1), 2013, 27-31.
12. Mohamed N, Amal E M, Morad A M, Manal A F. Prediction of gestational diabetes by measuring first trimester maternal serum uric acid concentration, *Journal of Basic and Clinical Reproductive Sciences*, 2(1), 2013, 27-31.
13. Akter S, Sultana S, Dabee S R. Association of hyperuricaemia with perinatal outcome in pregnancy induced hypertension, *Journal of Bangladesh College of Physicians and Surgeons*, 32(3), 2014, 124-129.
14. Berry C E, Hare J M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications, *J Physiol*, 555(3), 2004, 589-606.
15. Roger A, McMaster-Fay. Pre-eclampsia e a disease of oxidative stress resulting from the catabolism of DNA (primarily fetal) to uric acid by xanthine oxidase in the maternal liver: A hypothesis, *Bioscience Hypotheses*, 1, 2008, 35-43.

16. Huy A. Tran. Biochemical tests in pregnancy, *Australian Prescriber*, 28(4), 2005, 98-101.
17. Madazli R, Benian A, Gumustas K, Uzun H. Lipid peroxidation and antioxidants in preeclampsia, *European Journal of Obstetrics and Gynecology*, 85(2), 1999, 205-208.
18. James J, Walker. Severe pre-eclampsia and eclampsia, *Baillie Á re's Clinical Obstetrics and Gynaecology*, 14(1), 2000, 57-71.
19. Anne Barden, Lawrence J, Beilin, Jackie Ritchie, Kevin D, Croft, Barry N, Walters, Constantine A, Michael. Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy, *Clinical Science*, 9, 1996, 711-718.
20. Lowe S A, Bowyer L, Lust K, McMahon L, Morton M R, North R A, Paech M. Said J. The SOMANZ guideline for the management of hypertensive disorders of pregnancy, *Society of Obstetric Medicine of Australia and New Zealand (SOMANZ)*, 2014, 3-22.
21. Redman C W, Beilin L J, Bonnar J, Wilkinson R H. Plasma urate measurements in predicting fetal death in hypertensive pregnancy, *Lancet*, 1(7974), 1976, 1370-1373.
22. Varma T R. Serum uric acid levels as an index of foetal prognosis in pregnancies complicated by preexisting hypertension and preeclampsia of pregnancy, *Int J Gynaecol Obstet*, 20(5), 1982, 4018-18.
23. Mustaphi R, Gopalan S, Dhaliwal L, Sarkar A K. Hyperuricemia and pregnancy induced hypertension: Reappraisal, *Indian J Med Sci*, 50(3), 1996, 68-71.
24. Raijmakers M T, Roes E M, Te Morsche R H, Steegers E A, Peters W H. Haptoglobin and its association with the HELLP syndrome, *J Med Genet*, 40, 2003, 214-216.
25. Rizwana Habib Kant, Nousheen Mir, Safeena Sarwar³, Shruti Gupta, Rukhsana Najeeb. Role of Maternal Serum Lactate Dehydrogenase as a Biochemical Marker in Pre-Eclampsia, *Journal of Dental and Medical Sciences (JDMS)*, 14(7), 2015, 12-19.
26. Paneri S, Panchonia A, Varma M, Yadav S. Evaluation of RFTS, LFTS and ascorbic acid in pre-eclampsia among women of Indore, *Indian Journal of Fundamental and Applied Life Sciences*, 1(4), 2011, 312-315.
27. Basima S. Alghazali, Alaa M S, Nabras N H. The role of trace elements (zinc, copper, magnesium and calcium) in pregnant women with preeclampsia in third trimester and fetal cord blood after delivery, *Medical Journal of Al-Muthanna*, 1(1), 2014, 16-26.
28. ROCG guideline, the management of severe pre-eclampsia/eclampsia, Royal College of Obstetricians and Gynecologists, Guideline No.10 (A), 2010.
29. Remero R, Vizoso J, Emamian M, Duffy T, Riely C, Halford T *et al*. Clinical significance of liver dysfunction in pregnancy induced hypertension, *Am J Perinatol*, 5(2), 1988, 146-1451.
30. Leela K V, Lakshmi Kantham A, Kasibabu A. Evaluation of biochemical parameters in HELLP syndrome cases of pregnancy induced hypertension and eclampsia, *J of Evidence Based Med and Hthcare*, 2(26), 2015, 3914-3923.

Please cite this article in press as: Eltayeb Mohamed Ahmed Tayrab and Sohinda Saladdin. Biochemical and hematological evaluations in sudanese women with preeclampsia, *Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry*, 4(1), 2016, 1-7.